Autolus Therapeutics (STU:6A3A) Construction In Progress : €1.25 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Autolus Therapeutics Construction In Progress?

Autolus Therapeutics's quarterly construction in progress declined from Sep. 2023 (€17.09 Mil) to Dec. 2023 (€11.50 Mil) and declined from Dec. 2023 (€11.50 Mil) to Mar. 2024 (€1.25 Mil).

Autolus Therapeutics's annual construction in progress increased from Dec. 2021 (€2.16 Mil) to Dec. 2022 (€12.45 Mil) but then declined from Dec. 2022 (€12.45 Mil) to Dec. 2023 (€11.50 Mil).

Autolus Therapeutics Construction In Progress Historical Data

The historical data trend for Autolus Therapeutics's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Autolus Therapeutics Construction In Progress Chart

Autolus Therapeutics Annual Data

Trend

Sep16

Sep17

Sep18

Dec19

Dec20

Dec21

Dec22

Dec23

Construction In Progress

Get a 7-Day Free Trial

4.22

11.77

2.16

12.45

11.50

Autolus Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Construction In Progress	Get a 7-Day Free Trial															16.26	17.76	17.09	11.50	1.25

Autolus Therapeutics Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Autolus Therapeutics (STU:6A3A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Autolus Therapeutics PLC (STU:6A3A) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

AUTL:USA 6A3A:Germany

Address

191 Wood Lane, The MediaWorks, London, GBR, W12 7FP

Website

https://www.autolus.com

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Autolus Therapeutics (STU:6A3A) Headlines

No Headlines